Pharmacotherapy for pneumococcal infections: an update

Bibliography

• Andrade AL, Toscano CM, Minamisava R, Pneumococcal disease manifestation in children before and after vaccination: what is new? Vaccine 2011;29(Suppl 3):C2-14
   Google Scholar
• Lynch JP III, Zhanel GG. Streptococcus pneumoniae: epidemiology, risk factors, and strategies for prevention. Semin Respir Crit Care Med 2009;30:89-209
   Google Scholar
• O'Brien KL, Wolfson LJ, Watt JP, Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 2009;374:893-902
   PubMed Web of Science ®Google Scholar
• Obaro S, Adegbola R. The pneumococcus: carriage, disease and conjugate vaccines. J Med Microbiol 2002;51:98-104
   PubMed Web of Science ®Google Scholar
• Brugger SD, Hathaway LJ, Muhlemann K. Streptococcus pneumoniae strain co-colonization in the nasopharynx. J Clin Microbiol 2009;47:1750-6
   PubMed Web of Science ®Google Scholar
• Ward J. Antibiotic-resistant Streptococcus pneumoniae: clinical and epidemiologic aspects. Rev Infect Dis 1981;3:254-66
   PubMedGoogle Scholar
• Doern GV, Heilmann KP, Huynh HK, Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000, including a comparison of resistance rates since 1994 – 1995. Antimicrob Agents Chemother 2001;45:1721-9
   PubMed Web of Science ®Google Scholar
• Riedel S, Beekmann SE, Heilmann KP, Antimicrobial use in Europe and antimicrobial resistance in Streptococcus pneumoniae. Eur J Clin Microbiol Infect Dis 2007;26:485-90
   PubMed Web of Science ®Google Scholar
• Gladstone RA, Jefferies JM, Faust SN, Clarke SC. Continued control of pneumococcal disease in the UK – the impact of vaccination. J Med Microbiol 2011;60(Pt 1):1-8
   PubMed Web of Science ®Google Scholar
• Tan TQ. Serious and invasive pediatric pneumococcal disease: epidemiology and vaccine impact in the USA. Expert Rev Anti Infect Ther 2010;8:117-25
   PubMed Web of Science ®Google Scholar
• Dagan R. Impact of pneumococcal conjugate vaccine on infections caused by antibiotic-resistant Streptococcus pneumoniae. Clin Microbiol Infect 2009;15(Suppl 3):16-20
   PubMed Web of Science ®Google Scholar
• Cohen R, Levy C, Bonnet E, Dynamics of pneumococcal nasopharyngeal carriage in children with acute otitis media following PCV7 introduction in France. Vaccine 2010;28:6114-21
   PubMed Web of Science ®Google Scholar
• Aguiar SI, Serrano I, Pinto FR, Changes in Streptococcus pneumoniae serotypes causing invasive disease with non-universal vaccination coverage of the seven-valent conjugate vaccine. Clin Microbiol Infect 2008;14:835-43
   PubMed Web of Science ®Google Scholar
• Vestrheim DF, Høiby EA, Bergsaker MR, Indirect effect of conjugate pneumococcal vaccination in a 2 + 1 dose schedule. Vaccine 2010;28:2214-21
   PubMed Web of Science ®Google Scholar
• Harboe ZB, Benfield TL, Valentiner-Branth P, Temporal trends in invasive pneumococcal disease and pneumococcal serotypes over 7 decades. Clin Infect Dis 2010;50:329-37
   PubMed Web of Science ®Google Scholar
• Linares J, Ardanuy C, Pallares R, Fenoll A. Changes in antimicrobial resistance, serotypes and genotypes in Streptococcus pneumoniae over a 30-year period. Clin Microbiol Infect 2010;16:402-10
   PubMed Web of Science ®Google Scholar
• Brueggemann AB, Doern GV. Resistance among Streptococcus pneumoniae: patterns, mechanisms, interpreting the breakpoints. Am J Manag Care 2000;6(23 Suppl):S1189-96
   Google Scholar
• Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Twentieth informational supplement. Document M100-S20. CLSI; Wayne, PA: 2010
   Google Scholar
• Jones RN, Jacobs MR, Sader HS. Evolving trends in Streptococcus pneumoniae resistance: implications for therapy of community-acquired bacterial pneumonia. Int J Antimicrob Agents 2010;36:197-204
   PubMed Web of Science ®Google Scholar
• European Committee on Antimicrobial Susceptibility Testing. EUCAST. 2012. Available from: http://www.eucast.org/clinical-breakpoints/ [Accessed 19 September 2012]
   Google Scholar
• Song JH, Jung SI, Ko KS, High prevalence of antimicrobial resistance among clinical Streptococcus pneumoniae isolates in Asia (an ASNORP study). Antimicrob Agents Chemother 2004;48:2101-210
   PubMed Web of Science ®Google Scholar
• Johnson DM, Stilwell MG, Fritsche TR, Jones RN. Emergence of multidrug resistant Streptococcus pneumoniae: report from the SENTRY Antimicrobial Surveillance Program (1999 – 2003). Diagn Microbiol Infect Dis 2006;56:69-74
   PubMed Web of Science ®Google Scholar
• Cornick JE, Bentley SD. Streptococcus pneumoniae: the evolution of antimicrobial resistance to beta-lactams, fluoroquinolones and macrolides. Microb Infect 2012;14:573-83
   PubMedGoogle Scholar
• Lauderdale TL, Wagener MM, Lin HM, Serotype and antimicrobial resistance patterns of Streptococcus pneumoniae isolated from Taiwanese children: comparison of nasopharyngeal and clinical isolates. Diagn Microbiol Infect Dis 2006;56:421-6
   PubMed Web of Science ®Google Scholar
• Zhou L, Yu SJ, Gao W, Serotype distribution and antibiotic resistance of 140 pneumococcal isolates from pediatric patients with upper respiratory infections in Beijing, 2010. Vaccine 2011;29:7704-10
   PubMed Web of Science ®Google Scholar
• Schito GC, Felmingham D. Susceptibility of Streptococcus pneumoniae to penicillin, azithromycin and telithromycin (PROTEKT 1999 – 2003). Int J Antimicrob Agents 2005;26:479-85
   PubMed Web of Science ®Google Scholar
• Edelstein PH. Pneumococcal resistance to macrolides, lincosamides, ketolides and streptogramin B agents: molecular mechanisms and resistance phenotypes. Clin Infect Dis 2004;38(Suppl 4):S322-7
   Google Scholar
• Farrell DJ, Klugman KP, Pichichero M. Increased antimicrobial resistance among nonvaccine serotypes of Streptococcus pneumoniae in the pediatric population after the introduction of 7-valent pneumococcal vaccine in the United States. Pediatr Infect Dis J 2007;26:123-8
   PubMed Web of Science ®Google Scholar
• Ishimine P. Fever without source in children 0 to 36 months of age. Pediatr Clin North Am 2006;53:167-94
   PubMedGoogle Scholar
• Lagos RM, Munoz AE, Levine MM. Prevalence of pneumococcal bacteremia among children < 36 months of age presenting with moderate fever to pediatric emergency rooms of the Metropolitan Region (Santiago), Chile. Hum Vaccines 2006;2:129-33
   PubMed Web of Science ®Google Scholar
• Tarallo L, Tancredi F, Schito G, Active surveillance of Streptococcus pneumoniae bacteremia in Italian children. Vaccine 2006;24:6938-43
   Google Scholar
• Benito-Fernandez J, Raso SM, Pocheville-Gurutzeta I, Pneumococcal bacteremia among infants with fever without known source before and after introduction of pneumococcal conjugate vaccine in the Basque Country of Spain. Pediatr Infect Dis J 2007;26:667-71
   PubMed Web of Science ®Google Scholar
• Alpern ER, Alessandrini EA, McGowan KL, Serotype prevalence of occult pneumococcal bacteremia. Pediatrics 2001;108:E23
   PubMedGoogle Scholar
• Rothrock SG, Harper MB, Green SM, Do oral antibiotics prevent meningitis and serious bacterial infections in children with Streptococcus pneumoniae occult bacteremia? A meta-analysis. Pediatrics 1997;99:438-44
   Google Scholar
• Lynch JP III, Zhanel GG. Streptococcus pneumoniae: epidemiology and risk factors, evolution of antimicrobial resistance, and impact of vaccines. Curr Opin Pulm Med 2010;16:217-25
   PubMed Web of Science ®Google Scholar
• Tai SS. Streptococcus pneumoniae protein vaccine candidates: properties, activities and animal studies. Crit Rev Microbiol 2006;32:139-53
   PubMed Web of Science ®Google Scholar
• Zeretzke CM, McIntosh MS, Kalynych CJ, Reduced use of occult bacteremia blood screens by emergency medicine physicians using immunization registry for children presenting with fever without a source. Pediatr Emerg Care 2012;28:640-5
   Google Scholar
• Fonseca W, Hoppu K, Rey LC, Comparing pharmacokinetics of amoxicillin given twice or three times per day to children older than 3 months with pneumonia. Antimicrob Agents Chemother 2003;47:997-1001
   Google Scholar
• Andes D, Craig WA. In vivo activities of amoxicillin and amoxicillin-clavulanate against Streptococcus pneumoniae: application to breakpoint determinations. Antimicrob Agents Chemother 1998;42:2375-9
   PubMed Web of Science ®Google Scholar
• Nudelman Y, Tunkel AR. Bacterial meningitis. Epidemiology, pathogenesis and management updates. Drugs 2009;69:2577-96
   PubMed Web of Science ®Google Scholar
• Brouwer Tunkel AR, van de Beek D. Epidemiology, diagnosis, and antimicrobial treatment of acute bacterial meningitis. Clin Microb Rev 2010;23:467-92
   PubMed Web of Science ®Google Scholar
• Hsu HE, Shutt KA, Moore MR, Effect of pneumococcal conjugate vaccine on pneumococcal meningitis. N Engl J Med 2009;360:244-56
   PubMed Web of Science ®Google Scholar
• Lutsar I, McCracken GH Jr, Friedland IR. Antibiotic pharmacodynamics in cerebrospinal fluid. Clin Infect Dis 1998;27:1117-27
   PubMed Web of Science ®Google Scholar
• Chen Z, Wang Y, Zeng A, The clinical diagnostic significance of cerebrospinal fluid D-lactate for bacterial meningitis. Clin Chim Acta 2012;413:1512-15
   Google Scholar
• Hameed N, Tunkel AR. Treatment of drug resistant pneumococcal meningitis. Curr Infect Dis Rep 2010;12:274-81
   PubMedGoogle Scholar
• Tunkel AR, Hartman BJ, Kaplan SL, Practice guidelines for the management of bacterial meningitis. Clin Infect Dis 2004;39:1267-84
   PubMed Web of Science ®Google Scholar
• Viladrich PF, Gudiol F, Linares J, Evaluation of vancomycin for therapy of adult pneumococcal meningitis. Antimicrob Agents Chemother 1991;35:2467-72
   PubMed Web of Science ®Google Scholar
• Esposito S, Semino M, Picciolli I, Principi N. Should corticosteroids be used in bacterial meningitis in children? Eur J Paediatr Neurol 2012; Epub ahead of print
   Google Scholar
• Rodriguez CA, Atkinson R, Bitar W, Tolerance to vancomycin in pneumococci: detection with a molecular marker and assessment of clinical impact. J Infect Dis 2004;190:1481-7
   Google Scholar
• Odio CM, Puig JR, Feris JM, Prospective, randomized, investigator-blinded study of the efficacy and safety of meropenem vs. cefotaxime therapy in bacterial meningitis in children. Pediatr Infect Dis J 1999;18:581-90
   PubMed Web of Science ®Google Scholar
• Saez-Llorens X, McCoig C, Feris JM, Quinolone treatment for pediatric bacterial meningitis: a comparative study of trovafloxacin and ceftriaxone with or without vancomycin. Pediatr Infect Dis J 2002;21:14-22
   PubMed Web of Science ®Google Scholar
• American Academy of Pediatrics Subcommittee on Management of Acute Otitis Media. Diagnosis and management of acute otitis media. Pediatrics 2004;113:1451-65
   PubMed Web of Science ®Google Scholar
• Marchisio P, Bellussi L, Di Mauro G, Acute otitis media: from diagnosis to prevention. Summary of the Italian guideline. Int J Pediatr Otorhinolaryngol 2010;74:1209-16
   PubMed Web of Science ®Google Scholar
• Klein JO. Microbiologic efficacy of antibacterial drugs for acute otitis media. Pediatr Infect Dis J 1993;12:973-5
   PubMedGoogle Scholar
• Dagan R, Abramson O, Leibovitz E, Bacteriologic response to oral cephalosporins: are established susceptibility breakpoints appropriate in the case of acute otitis media? J Infect Dis 1997;176:1253-9
   Google Scholar
• Craig WA, Andes D. Pharmacokinetics and pharmacodynamics of antibiotics in otitis media. Pediatr Infect Dis J 1996;15:255-9
   PubMed Web of Science ®Google Scholar
• Blumer JL. Implications of pharmacokinetics in making choices for the management of acute otitis media. Pediatr Infect Dis J 1998;17:565-70
   Google Scholar
• Seikel K, Shelton S, McCracken GH Jr. Middle ear fluid concentrations of amoxicillin after large dosages in children with acute otitis media. Pediatr Infect Dis J 1997;16:710-11
   PubMed Web of Science ®Google Scholar
• Piglansky L, Leibovitz E, Raiz S, Bacteriologic and clinical efficacy of high dose amoxicillin for therapy of acute otitis media in children. Pediatr Infect Dis J 2003;22:405-13
   PubMed Web of Science ®Google Scholar
• Pichichero ME, Casey JR, Hoberman A, Schwartz R. Pathogens causing recurrent and difficult-to-treat acute otitis media, 2003-2006. Clin Pediatr (Phila) 2008;47:901-6
   PubMed Web of Science ®Google Scholar
• Ongkasuwan J, Valdez TA, Hulten KG, Pneumococcal mastoiditis in children and the emergence of multidrug-resistant serotype 19A isolates. Pediatrics 2008;122:34-9
   PubMed Web of Science ®Google Scholar
• Xu Q, Pichichero ME, Casey JR, Zeng M. Novel type of Streptococcus pneumoniae causing multidrug-resistant acute otitis media in children. Emerg Infect Dis 2009;15:547-51
   PubMedGoogle Scholar
• Gilani Z, Kwong YD, Levine OS, A literature review and survey of childhood pneumonia etiology studies: 2000 – 2010. Clin Infect Dis 2012;54(Suppl 2):102-8
   PubMed Web of Science ®Google Scholar
• Esposito S, Principi N. Unsolved problems in the approach to pediatric community-acquired pneumonia. Curr Opin Infect Dis 2012;25:286-91
   PubMed Web of Science ®Google Scholar
• Harris M, Clark J, Coote N, British Thoracic Society guidelines for the management of community acquired pneumonia in children: update 2011. Thorax 2011;66(Suppl 2):1-23
   Google Scholar
• Esposito S, Cohen R, Domingo JD, Antibiotic therapy for pediatric community-acquired pneumonia: do we know when, what and for how long to treat? Pediatr Infect Dis J 2012;31:e78-85
   PubMed Web of Science ®Google Scholar
• Bradley JS, Byington CL, Shah SS, The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clin Infect Dis 2011;53:e25-76
   PubMed Web of Science ®Google Scholar
• Esposito S, Marchese A, Tozzi AE, Bacteremic pneumococcal community-acquired pneumonia in children less than 5 years of age in Italy. Pediatr Infect Dis J 2012;31:705-10
   PubMed Web of Science ®Google Scholar
• Grijalva CG, Nuorti JP, Arbogast PG, Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet 2007;369:1179-86
   PubMed Web of Science ®Google Scholar
• Patrzałek M, Albrecht P, Sobczynski M. Significant decline in pneumonia admission rate after the introduction of routine 2+1 dose schedule heptavalent pneumococcal conjugate vaccine (PCV7) in children under 5 years of age in Kielce, Poland. Eur J Clin Microbiol Infect Dis 2010;29:787-92
   PubMed Web of Science ®Google Scholar
• Yu J, Salamon D, Marcon M, Nahm MH. Pneumococcal serotypes causing pneumonia with pleural effusion in pediatric patients. J Clin Microbiol 2011;49:534-8
   PubMed Web of Science ®Google Scholar
• Picazo J, Ruiz-Contreras J, Hernandez B, Clonal and clinical profile of Streptococcus pneumoniae serotype 19A causing pediatric invasive infections: a 2-year (2007–2009) laboratory-based surveillance in Madrid. Vaccine 2011;29:1770-6
   PubMed Web of Science ®Google Scholar
• Chibuk TK, Robinson JL, Hartfield DS. Pediatric complicated pneumonia and pneumococcal serotype replacement: trends in hospitalized children pre and post introduction of routine vaccination with Pneumococcal Conjugate Vaccine (PCV7). Eur J Pediatr 2010;169:1123-8
   PubMed Web of Science ®Google Scholar
• Kiem S, Schentag JJ. Interpretation of antibiotic concentration ratios measured in epithelial lining fluid. Antimicrob Agents Chemother 2008;52:24-36
   PubMed Web of Science ®Google Scholar
• Woodnutt G, Berry V. Efficacy of high-dose amoxicillin-clavulanate against experimental respiratory tract infections caused by strains of Streptococcus pneumoniae. Antimicrob Agents Chemother 1999;43:35-40
   PubMed Web of Science ®Google Scholar
• Lynch JP III, Zhanel GG. Streptococcus pneumoniae: does antimicrobial resistance matter? Semin Respir Crit Care Med 2009;30:210-38
   PubMed Web of Science ®Google Scholar
• Pallares R, Linares J, Vadillo M, Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N. Engl J Med 1995;333:474-80
   PubMed Web of Science ®Google Scholar
• Tan TQ, Mason EO Jr, Wald ER, Clinical characteristics of children with complicated pneumonia caused by Streptococcus pneumoniae. Pediatrics 2002;110:1-6
   PubMed Web of Science ®Google Scholar
• Yu VL, Chiou CC, Feldman C, An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered, and clinical outcome. Clin Infect Dis 2003;37:230-7
   PubMed Web of Science ®Google Scholar
• Paganini H, Guinazu JR, Hernandez C, Comparative analysis of outcome and clinical features in children with pleural empyema caused by penicillin-nonsusceptible and penicillin-susceptible Streptococcus pneumoniae. Int J Infect Dis 2001;5:86-8
   Google Scholar
• Kabra SK, Lodha R, Pandey RM. Antibiotics for community-acquired pneumonia in children. Cochrane Database Syst Rev 2010;3:CD004874
   Google Scholar
• Turret GS, Blum S, Fazal BA, Penicillin resistance and other predictors of mortality in pneumococcal bacteremia in a population with high HIV seroprevalence. Clin Infect Dis 1999;29:321-7
   Google Scholar
• Dowell SF, Smith T, Leversedge K, Snitzer J. Pneumonia treatment failure associated with highly resistant pneumococci. Clin Infect Dis 1999;29:462-3
   PubMed Web of Science ®Google Scholar
• Choi E, Lee H. Clinical outcome of invasive infections by penicillin-resistant Streptococcus pneumoniae in Korean children. Clin Infect Dis 1998;26:1346-54
   PubMed Web of Science ®Google Scholar
• American Academy of Pediatrics Committee on Infectious Diseases. Therapy for children with invasive pneumococcal infections. Pediatrics 1997;99:289-99
   Google Scholar
• Chiappini E, Conti C, Galli L, de Martino M. Clinical efficacy and tolerability of linezolid in pediatric patients: a systematic review. Clin Ther 2010;32:66-88
   PubMed Web of Science ®Google Scholar
• Davies TA, Flamm RK, Lynch AS. Activity of ceftobiprole against Streptococcus pneumoniae isolates exhibiting high-level resistance to ceftriaxone. Int J Antimicrob Agents 2012;39:534-8
   PubMed Web of Science ®Google Scholar
• Nicholson SC, Welte T, File TM Jr, A randomised, double-blind trial comparing ceftobiprole medocaril with ceftriaxone with or without linezolid for the treatment of patients with community-acquired pneumonia requiring hospitalisation. Int J Antimicrob Agents 2012;39:240-6
   PubMed Web of Science ®Google Scholar
• File TM Jr, Wilmox MH, Stein GE. Summary of ceftaroline fosemil clinical trial studies and clinical safety. Clin Infect Dis 2012;55(S3):173-80
   Google Scholar
• Maselli DJ, Fernandez JF, Whong CY, Clinical evaluation of the role of ceftaroline in the management of community acquired bacterial pneumonia. Infect Drug Resist 2012;5:43-51
   PubMedGoogle Scholar
• Falco V, Sanchez A, Pahissa A, Rello J. Emerging drugs for pneumococcal pneumonia. Expert Opin Emerg Drugs 2011;16:459-77
   PubMed Web of Science ®Google Scholar
• Cohen R, Levy C, Bingen E, Nasopharyngeal carriage in healthy children before and after 13-valent pneumococcal conjugate vaccine implementation [abstract G-1049]. Proceedings of the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 9 – 12 September 2012; San Francisco, CA
   Google Scholar
• Miller E, Andrews NJ, Waight PA, Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine. Vaccine 2011;29:9127-31
   PubMed Web of Science ®Google Scholar
• Vergison A. Pneumococcal Conjugates: impact of expanded valent vaccines [abstract 439]. Proceedings of the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 9 – 12 September 2012; San Francisco, CA
   Google Scholar
• Levy C, Varon E, Bingen E, Effect of 7-valent and 13-valent pneumococcal conjugate vaccines on pneumococcal meningitis in French children under 2 years [abstract G-864]. Proceedings of the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 9 – 12 September 2012; San Francisco, CA
   Google Scholar
• Principi N, Esposito S. Universal protein vaccines against Neisseria meningitidis serogroup B, Streptococcus pneumoniae and influenza. Hum Vaccin 2011;7:905-12
   PubMed Web of Science ®Google Scholar